Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mimi Flensburg"'
Autor:
Brian K. Link, Pieter Sonneveld, Michael Kneba, Marek Z. Wojtukiewicz, Ole V. Gadeberg, Peter Johnson, John Radford, Jørgen Petersen, Michael Pfreundschuh, Nedjad Losic, Andreas Engert, Anton Hagenbeek, Lars Møller Pedersen, Tadeusz Robak, Jan Walewski, Mimi Flensburg, Andrzej Hellmann
Publikováno v:
Hagenbeek, A, Gadeberg, O V, Johnson, P, Pedersen, L M, Walewski, J, Hellmann, A, Link, B K, Robak, T, Wojtukiewicz, M, Pfreundschuh, M, Kneba, M, Engert, A, Sonneveld, P, Flensburg, M, Petersen, J, Losic, N & Radford, J 2008, ' First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma : results of a phase 1/2 trial ', Blood, vol. 111, no. 12, pp. 5486-5495 . https://doi.org/10.1182/blood-2007-10-117671
Blood, 111(12), 5486-5495. American Society of Hematology
Blood, 111(12), 5486-5495. American Society of Hematology
Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell lymphoma/chronic lymphocytic leukemia cells with low CD20-antigen density and h
Autor:
Janusz Kloczko, Lars Møller Pedersen, Jerzy Holowiecki, Tadeusz Robak, Mimi Flensburg, Andrzej Hellmann, Bertrand Coiffier, James E. Wooldridge, Henrik Fredriksen, Ole V. Gadeberg, Stéphane Leprêtre, Jan Walewski, Marinus H. J. van Oers, Jørgen Petersen
Publikováno v:
Coiffier, B, Lepretre, S, Pedersen, L M, Gadeberg, O, Fredriksen, H, van Oers, M H J, Wooldridge, J, Kloczko, J, Holowiecki, J, Hellmann, A, Walewski, J, Flensburg, M, Petersen, J & Robak, T 2008, ' Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia : a phase 1-2 study ', Blood, vol. 111, no. 3, pp. 1094-1100 . https://doi.org/10.1182/blood-2007-09-111781
Blood, 111(3), 1094-1100. American Society of Hematology
Blood, 111(3), 1094-1100. American Society of Hematology
Safety and efficacy of the fully human anti-CD20 monoclonal antibody, ofatumumab, was analyzed in a multicenter dose-escalating study including 33 patients with relapsed or refractory chronic lymphocytic leukemia. Three cohorts of 3 (A), 3 (B), and 2
Autor:
Jan Walewski, Lars Møller Pedersen, Janusz Kloczko, Tadeusz Robak, Jerzy Holowiecki, M. H. J. Van Oers, Jørgen Petersen, Trine Lindhardt Plesner, H. Tilly, Mimi Flensburg, Henrik Frederiksen, Bertrand Coiffier, James E. Wooldridge, Andrzej Hellmann
Publikováno v:
Blood. 108:2842-2842
Background: The fully human monoclonal IgG1 antibody HuMax-CD20 targets a novel epitope of the CD20 molecule on B-cells. HuMax-CD20 stops growth of engrafted B-cell tumors in SCID mice more efficiently than Rituximab and i.v. infusion of HuMax-CD20 i
Autor:
Trine Lindhardt Plesner, Tadeusz Robak, J. J. Walewski, Mimi Flensburg, M. H. J. Van Oers, Andrzej Hellmann, Henrik Frederiksen, Lars Møller Pedersen, Bertrand Coiffier, James E. Wooldridge, Janusz Kloczko, H. Tilly, Jerzy Holowiecki, Jørgen Petersen
Publikováno v:
Blood. 106:448-448
The fully human monoclonal IgG1 antibody HuMax-CD20 targets a novel epitope of the CD20 molecule on B-cells. HuMax-CD20 stops growth of engrafted B-cell tumors in SCID mice more efficiently than Rituximab and i.v. infusion of HuMax-CD20 in cynomolgus